U.S., June 4 -- ClinicalTrials.gov registry received information related to the study (NCT07623850) titled 'A Phase I Study of JLM019 Injection' on May 18.
Brief Summary: This is a multicenter, single-arm, open-label, dose escalation phase (Part A) and dose expansion (Part B) study to evaluate the safety and tolerability of JLM019 Injection in patients with advanced malignancies.
The study subjects are adults with advanced malignancies including advanced solid tumors or relapsed/refractory lymphoma.
During the dose escalation phase, the dose escalation scheme is the accelerated titration in 0.001 - 0.2 mg/kg cohorts plus a traditional '3 + 3' design in 0.6 - 10 mg/kg cohorts, jointly in nine dose cohorts 0.001, 0.01, 0.05, 0.2, 0.6, 1.5,...